Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

MoneyGroupLLC Dec. 24 at 1:35 PM

Enter: $OLMA Calls Strike Price: $28 Expiry Date: JAN 16 2026 Buy in Price: $2.55 - $2.68 Sell Price: $5.02 Profit : +97% (Turn every $1 into $1.97) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Djjazzyjeff Dec. 23 at 9:53 PM

$OLMA lots of bag holders here how it going guys

2 · Reply

GSP Dec. 23 at 12:44 AM

$OLMA may have found support at the 20-day moving average today. .

0 · Reply

GSP Dec. 22 at 9:32 PM

$SPY $OLMA $RZLT $QCLS $CCCX

0 · Reply

MoneyGroupLLC Dec. 22 at 7:42 PM

Enter: $OLMA Calls Strike Price: $28 Expiry Date: JAN 16 2026 Buy in Price: $3.30 - $8.50 Sell Price: $13.94 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Keystone1 Dec. 22 at 4:10 PM

$OLMA Green! Hopefully over 30 soon then on to new highs!

0 · Reply

GSP Dec. 22 at 12:51 PM

$RKLB $ONDS $NBY $VOR $OLMA

0 · Reply

MoneyGroupLLC Dec. 20 at 6:38 PM

Enter: $OLMA Calls Strike Price: $28 Expiry Date: JAN 16 2026 Buy in Price: $4.80 - $8.50 Sell Price: $16.91 Profit : +99% (Turn every $1 into $1.99) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

AnyaGirl Dec. 19 at 7:17 PM

$OLMA Scaring out people before 100$ will buy back in after it dumps more

1 · Reply

Chrissytina Dec. 19 at 6:42 PM

$OCGN $OLMA $PHIO $SAVA $SNGX This is the only moon that stock will ever see 🤭 gtfoh

1 · Reply

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Nov 21, 2025, 4:30 PM EST - 4 weeks ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 4:01 PM EST - 5 weeks ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 18, 2025, 4:51 PM EST - 5 weeks ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 18, 2025, 4:21 PM EST - 5 weeks ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO PFE

Nov 18, 2025, 12:01 PM EST - 5 weeks ago

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Nov 18, 2025, 10:21 AM EST - 5 weeks ago

OLMA stock: could today's 197% surge be just the beginning?

Nov 18, 2025, 9:56 AM EST - 5 weeks ago

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Nov 10, 2025, 7:00 AM EST - 6 weeks ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Nov 4, 2025, 4:30 PM EST - 7 weeks ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 4:30 PM EST - 7 weeks ago

Olema Oncology to Participate in Upcoming Investor Conferences

Oct 30, 2025, 4:30 PM EDT - 2 months ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 3:25 PM EDT - 2 months ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 18, 2025, 3:00 AM EDT - 2 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 11, 2025, 4:01 PM EDT - 4 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 7 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 8 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 8 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 9 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 9 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 10 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 11 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 1 year ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 2 years ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 2 years ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 2 years ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 2 years ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 2 years ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 2 years ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

MoneyGroupLLC Dec. 24 at 1:35 PM

0 · Reply

Djjazzyjeff Dec. 23 at 9:53 PM

$OLMA lots of bag holders here how it going guys

2 · Reply

GSP Dec. 23 at 12:44 AM

$OLMA may have found support at the 20-day moving average today. .

0 · Reply

GSP Dec. 22 at 9:32 PM

$SPY $OLMA $RZLT $QCLS $CCCX

0 · Reply

MoneyGroupLLC Dec. 22 at 7:42 PM

0 · Reply

Keystone1 Dec. 22 at 4:10 PM

$OLMA Green! Hopefully over 30 soon then on to new highs!

0 · Reply

GSP Dec. 22 at 12:51 PM

$RKLB $ONDS $NBY $VOR $OLMA

0 · Reply

MoneyGroupLLC Dec. 20 at 6:38 PM

0 · Reply

AnyaGirl Dec. 19 at 7:17 PM

$OLMA Scaring out people before 100$ will buy back in after it dumps more

1 · Reply

Chrissytina Dec. 19 at 6:42 PM

$OCGN $OLMA $PHIO $SAVA $SNGX This is the only moon that stock will ever see 🤭 gtfoh

1 · Reply

MoneyGroupLLC Dec. 19 at 6:12 PM

Enter: $OLMA Calls Strike Price: $31 Expiry Date: JAN 16 2026 Buy in Price: $2.65 - $3.20 Sell Price: $5.03 Profit : +90% (Turn every $1 into $1.90) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Stock__Hunter Dec. 19 at 4:21 PM

$OLMA gonna miss ol ma's cooking

0 · Reply

MoneyGroupLLC Dec. 18 at 5:42 PM

Enter: $OLMA Calls Strike Price: $33 Expiry Date: JAN 16 2026 Buy in Price: $3.30 - $5.00 Sell Price: $9.40 Profit : +88% (Turn every $1 into $1.88) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

N8LongShort Dec. 18 at 12:56 PM

$ATHA $OLMA 2.0

0 · Reply

MoneyGroupLLC Dec. 16 at 4:43 PM

Enter: $OLMA Calls Strike Price: $37 Expiry Date: JAN 16 2026 Buy in Price: $3.14 - $3.50 Sell Price: $5.84 Profit : +86% (Turn every $1 into $1.86) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

DARKP00L Dec. 15 at 8:54 PM

$OLMA this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

kshonstocks Dec. 15 at 6:49 PM

$OLMA impressive today

0 · Reply

thehivemindfund Dec. 15 at 5:06 PM

$OLMA massive unloading of shares. take your bets.

1 · Reply

MOOSEN Dec. 15 at 4:08 PM

$OLMA GIDDY UP.

0 · Reply

Stock__Hunter Dec. 15 at 3:27 PM

$OLMA strong like

0 · Reply

AnyaGirl Dec. 15 at 2:18 PM

$OLMA devastated that i sold this at 8$. i knew it would rip one day, but wanted a faster opportunity. 💔 its going to 100.

0 · Reply

Stock__Hunter Dec. 15 at 5:13 AM

$OLMA 50ma on monthly @ 8.00 thats why big moves happen. daily/weekly...

0 · Reply

Market Cap	1.90B
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	1,029,800
Avg Vol	4,476,064
Day's Range	N/A - N/A
Shares Out	68.66M
Stochastic %K	15%
Beta	1.87
Analysts	Strong Sell
Price Target	$46.00